SecBot SecBot

OGEN

ORAGENICS INC
NYSE· Pharmaceutical Preparations· Inc. FL· CIK 0001174940 Biotech & Drug Discovery
$0.3985 −0.02 (−5.12%)
Oct 26 4:00 PM ET · prev $0.4200
Market cap
$1.8M
Nano cap
Next earnings
Nov 5
in 10 days
1 year
−70.0%
from $1.33 · Oct 27
30 days
−15.2%
from $0.4700
52-week range
$0.3985–1.33
at the low
Avg volume 20D
22.1K
shares / day
Short interest
841.6K
≈18.6% of shares · +4.3%
Days to cover
24.9
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 5, 2026
Strongest BEARISH Oragenics received a delisting notice from NYSE American on August 26, 2026, for failing to meet…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 2 trimmed or exited.

  • Short sellersSTEADY

    Short interest +4.3% to 841.6K shares. 24.9 days to cover, ≈18.6% of shares.

  • TrendDOWNTREND

    18% below its 50-day average. New closing low $0.3985 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADADOUBLED2—
GEODE CAPITAL MANAGEMENT, LLCTRIM23,685$13.8K
UBS Group AGNEAR_EXIT642$373.00
UBS Group AGDOUBLED5,205$2.9K
UBS Group AGDOUBLED2,394$1.9K
UBS Group AGNEAR_EXIT271$355.00
MORGAN STANLEYNEAR_EXIT138$181.00
BANK OF AMERICA CORP /DE/NEAR_EXIT36$47.00

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
OGEN Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Aug 28, 2026
Press release
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing…
Aug 6, 2026
Earnings date
OGEN Q2 2026 Earnings Scheduled — 2026-08-06
May 19, 2026
Press release
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage…
May 18, 2026
Press release
ORAGENICS PROVIDES INVESTOR UPDATE
A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER
May 7, 2026
Earnings date
OGEN Q1 2026 Earnings Scheduled — 2026-05-07

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 1, 2026
Spencer John
Chief Financial Officer
AWARD55,900 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
841,634
shares short
+4.3%
vs prior settlement
24.9
days to cover
≈18.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 16, 2026 SEC
Oragenics filed an 8-K announcing its Chief Medical Officer will present at the IPAC-RS 2026 Nasal Innovation Forum…
8-K — Impact 3/10
Aug 28, 2026 SEC
Oragenics received a delisting notice from NYSE American on August 26, 2026, for failing to meet stockholders' equity…
8-K — Impact 7/10
Aug 28, 2026 Other
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-
Jul 1, 2026 Insider
Spencer John was granted 55,900 shares
Chief Financial Officer
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — DOUBLED
2 shares (—)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
23,685 shares ($13.8K)
May 20, 2026 SEC
Oragenics Inc filed a DEFA14A (definitive additional proxy soliciting materials) on May 20, 2026. The filing is…
DEFA14A — Impact 6/10
Mar 25, 2026 Press
Oragenics issued a press release to comply with NYSE American rules, confirming that its audited financial statements…
Impact 7/10

SecBot reports

8 filings · 2 press releases · 0 bullish · 1 bearish · 7 neutral
All OGEN filing & press-release reports (10)